Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMNMNASDAQ:INBXNASDAQ:NRIXNASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMNMImmunome$8.86-1.0%$7.65$5.15▼$16.81$770.93M2913,655 shs1.21 million shsINBXInhibrx$13.56-1.4%$12.40$10.80▼$18.95$196.30MN/A117,595 shs76,321 shsNRIXNurix Therapeutics$10.62-0.2%$10.35$8.18▼$29.56$809.63M2.23868,191 shs922,966 shsPHARPharming Group$10.90+8.7%$8.95$6.65▼$11.07$741.20M-0.086,432 shs907 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMNMImmunome0.00%+4.36%+0.11%-0.89%-40.70%INBXInhibrx0.00%+5.44%+11.60%-0.15%-16.55%NRIXNurix Therapeutics0.00%+9.26%-5.77%-25.16%-32.57%PHARPharming Group0.00%+4.51%+20.80%+20.85%+19.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMNMImmunome2.7529 of 5 stars4.52.00.00.01.62.50.0INBXInhibrx2.2847 of 5 stars0.01.00.04.63.82.51.3NRIXNurix Therapeutics2.1928 of 5 stars4.40.00.00.03.50.80.0PHARPharming Group2.5314 of 5 stars3.55.00.00.02.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMNMImmunome 3.00Buy$23.33163.36% UpsideINBXInhibrx 2.00HoldN/AN/ANRIXNurix Therapeutics 2.84Moderate Buy$30.44186.67% UpsidePHARPharming Group 3.00Buy$30.00175.36% UpsideCurrent Analyst Ratings BreakdownLatest INBX, NRIX, IMNM, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025INBXInhibrxJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.004/29/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/9/2025NRIXNurix TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $25.004/9/2025NRIXNurix TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $35.004/9/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $27.004/2/2025IMNMImmunomeLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.004/2/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/20/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $25.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMNMImmunome$10.94M70.48N/AN/A$2.77 per share3.20INBXInhibrx$200K981.47N/AN/AN/A∞NRIXNurix Therapeutics$56.42M14.35N/AN/A$7.44 per share1.43PHARPharming Group$320.71M2.31$0.12 per share91.82$3.26 per share3.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMNMImmunome-$106.81M-$3.18N/AN/AN/A-3,014.59%-48.63%-41.62%8/11/2025 (Estimated)INBXInhibrx-$154.96M$116.750.12N/AN/AN/A-113.74%-80.56%6/16/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.80N/AN/AN/A-354.85%-53.65%-38.59%7/10/2025 (Estimated)PHARPharming Group-$10.55M-$0.20N/A363.17N/A-6.09%-7.65%-3.82%7/30/2025 (Estimated)Latest INBX, NRIX, IMNM, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q4 2024INBXInhibrx-$2.55-$2.80-$0.25-$2.80N/AN/A5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million4/8/2025Q1 2025NRIXNurix Therapeutics-$0.72-$0.67+$0.05-$0.67$12.78 million$18.45 million3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 million3/17/2025Q4 2024INBXInhibrx-$2.88-$3.09-$0.21-$3.09N/A$0.10 million3/13/2025Q4 2024PHARPharming Group$0.07$0.05-$0.02$0.05$76.67 million$92.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMNMImmunomeN/AN/AN/AN/AN/AINBXInhibrxN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMNMImmunomeN/A6.176.17INBXInhibrxN/A4.704.70NRIXNurix TherapeuticsN/A6.466.46PHARPharming Group0.413.532.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMNMImmunome44.58%INBXInhibrx82.46%NRIXNurix TherapeuticsN/APHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipIMNMImmunome8.60%INBXInhibrx17.09%NRIXNurix Therapeutics7.40%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMNMImmunome4087.01 million72.92 millionOptionableINBXInhibrx16614.48 million11.26 millionOptionableNRIXNurix Therapeutics30076.24 million70.42 millionOptionablePHARPharming Group28068.03 million66.62 millionNot OptionableINBX, NRIX, IMNM, and PHAR HeadlinesRecent News About These CompaniesPharming Group (NASDAQ:PHAR) Shares Up 10.1% - Should You Buy?June 1 at 3:21 AM | americanbankingnews.comPharming Group (NASDAQ:PHAR) Stock Price Up 10.1% - Here's What HappenedMay 31 at 12:48 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Here's What HappenedMay 30 at 4:15 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?May 29, 2025 | marketbeat.comPharming Group to participate in June investor conferencesMay 28, 2025 | finance.yahoo.comPharming Group to participate in June investor conferences | PHARM Stock NewsMay 28, 2025 | gurufocus.comQ2 EPS Estimates for Pharming Group Decreased by AnalystMay 13, 2025 | marketbeat.comPharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)May 10, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comPharming Group N.V. 2025 Q1 - Results - Earnings Call PresentationMay 9, 2025 | seekingalpha.comPharming Group’s Strong Financial Performance and Strategic Growth Drive Buy RatingMay 8, 2025 | tipranks.comPharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business updateMay 8, 2025 | finanznachrichten.dePharming Group reports first quarter 2025 financial results and provides business updateMay 8, 2025 | taiwannews.com.twPharming Group reports first quarter 2025 financial results and provides business update | ...May 8, 2025 | gurufocus.comEarnings To Watch: Pharming Group (PHGUF) Reports Q1 2025 ResultMay 7, 2025 | gurufocus.comPharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive DirectorApril 30, 2025 | finance.yahoo.comPharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of ...April 30, 2025 | gurufocus.comPharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical ...April 25, 2025 | gurufocus.comPharming Group to Present Key Findings at Clinical Immunology Society MeetingApril 25, 2025 | tipranks.comPharming receives positive recommendation from NICE for Joenja®?(leniolisib) as a treatment for APDSApril 24, 2025 | tmcnet.comPharming receives positive recommendation from NICE for Joenja to treat APDS in adult and paediatric patients 12 years of age and olderApril 24, 2025 | pharmabiz.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINBX, NRIX, IMNM, and PHAR Company DescriptionsImmunome NASDAQ:IMNM$8.86 -0.09 (-1.01%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$8.76 -0.10 (-1.13%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Inhibrx NASDAQ:INBX$13.56 -0.19 (-1.38%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$13.47 -0.09 (-0.66%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Nurix Therapeutics NASDAQ:NRIX$10.62 -0.02 (-0.19%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$10.63 +0.01 (+0.09%) As of 05:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Pharming Group NASDAQ:PHAR$10.90 +0.88 (+8.73%) Closing price 05/30/2025 03:44 PM EasternExtended Trading$10.60 -0.30 (-2.71%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
